Fear is a conscious state caused by exposure to real or imagined threats that trigger stress responses that affect the body and brain, particularly limbic structures. A sub-group of patients with mesial temporal lobe epilepsy related to hippocampus sclerosis (MTLE-HS) have seizures with fear, which is called ictal fear (IF), due to epileptic activity within the brain defensive survival circuit structures. Synaptic transmission efficacy can be bi-directionally modified through potentiation (long-term potentiation (LTP)) or depression (long-term depression (LTD)) as well as the phosphorylation state of Ser831 and Ser845 sites at the GluA1 subunit of the glutamate AMPA receptors, which has been characterized as a critical event for this synaptic plasticity. In this study, GluA1 levels and the phosphorylation at Ser845 and Ser831 in the amygdala (AMY), anterior hippocampus (aHIP) and middle gyrus of temporal neocortex (CX) were determined with western blots and compared between MTLE-HS patients who were showing (n = 06) or not showing (n = 25) IF. Patients with IF had an 11% decrease of AMY levels of the GluA1 subunit (p = 0.05) and a 21.5% decrease of aHIP levels of P-GluA1-Ser845 (p = 0.009) compared to patients not showing IF. The observed associations were not related to imbalances in the distribution of other concomitant types of aura, demographic, clinical or neurosurgical variables. The lower levels of P-GluA1-Ser845 in the aHIP of patients with IF were not related to changes in the levels of the serine/threonine-protein phosphatase PP1-alpha catalytic subunit or protein kinase A activation. Taken together, the GluA1 subunit levels in AMY and P-GluA1-Ser845 levels in the aHIP show an overall accuracy of 89.3% (specificity 95.5% and sensitivity 66.7%) to predict the presence of IF. AMY levels of the GluA1 subunit and aHIP levels of P-GluA1-Ser845 were not associated with the psychiatric diagnosis and symptoms of patients. Taken together with previous findings in MTLE-HS patients with IF who were evaluated by stereotactic implanted depth electrodes, we speculate our findings are consistent with the hypothesis that AMY is not a centre of fear but together with other sub-cortical and cortical structures integrates the defensive circuit that detect and respond to threats. This is the first report to address neuroplasticity features in human limbic structures connected to the defensive survival circuits, which has implications for the comprehension of highly prevalent psychiatric disorders and symptoms.
Introduction
Fear is a distinct and recognized human emotion that is considered to be a conscious state caused by exposure to real or imagined threats [1, 2] . Defensive survival circuits detect and respond to threats, which initiates stress responses in the brain and body that indirectly contribute to conscious fear [2] . In predisposed individuals, acute and intense stress has been associated with post-traumatic stress disorder, and chronic and repetitive stress has been associated with depression and anxiety disorders [3] .
Epilepsies are characterized by recurrent spontaneous hyperexcitable and hypersynchronic brain activity [4, 5] that occurs in approximately 0.5 to 1% of the world population. Thirty percent of all patients who have drugresistant epilepsy are candidates for pre-surgical evaluation [6] . Mesial temporal lobe epilepsy related to hippocampus sclerosis (MTLE-HS) is the most common type of surgically treatable epilepsy [7] [8] [9] . In MTLE-HS, the hippocampus (HIP) is involved in seizure onset for 48.5% of cases, the amygdala (AMY) is involved in 26.7% of cases and synchronous onset in the two structures occurs for the remaining 24 .8% of cases [10] . Before consciousness is impaired, patients can become aware of their seizure symptoms in a phenomenon called epileptic aura [11] . The typical MTLE-HS aura includes olfactory, abdominal, autonomic, cephalic or psychic sensations, including déjà-vu, jamais-vu and fear [12, 13] . The aura of fear, which is also termed ictal fear (IF), is characterized by a sudden, often short, conscious state of fear that occurs during the seizure and is unrelated to any real or imagined threats, including the fear of a seizure itself [13] [14] [15] [16] . In MTLE-HS patients evaluated with stereotactic implanted depth electrodes, the IF sensation and associated behaviour occurred when epileptic discharges involved or interfered with orbito-prefrontal, anterior cingulate and temporal limbic cortices but did not occur if only the AMY was activated by the epileptic discharge. Interestingly, sensation of fear without associated behavioural changes can be evoked by electric stimulation of the AMY [15] .
Active synapses are bi-directionally modifiable in brain regions, such as the AMY, HIP and neocortex [17, 18] . A long-lasting increase in synaptic transmission, called longterm potentiation (LTP), is usually induced by highfrequency neuronal stimulation [17] . Decreases in synaptic efficacy are caused by long-term depression (LTD) after low-frequency stimulation (LFS) [17] . The in vivo pharmacological evidence suggests that there is an association between LTP and the fear associative memory task one-trial inhibitory avoidance [19] [20] [21] [22] , which is thought to induce LTP in the HIP [23] . Fear conditioning, which is another fear associative memory task, can be inactivated by LTD and reactivated by LTP in the AMY, which supports a causal link between these synaptic processes and fear associative memory [18] . AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors are heterotetrameric assemblies of GluA1-4 subunits, and the phosphorylation states of Ser831 and Ser845 of the GluA1 subunit are involved in LTP and LTD [24] [25] [26] [27] [28] [29] . LTP induction increases the phosphorylation of both sites [28, 29] . Conversely, in naive synapses, LTD induction dephosphorylates Ser845, whereas in potentiated synapses, Ser831 is dephosphorylated by LTD induction. The level of GluA1 subunit phosphorylation on the Ser831 and Ser845 sites can be used as biomarkers of synaptic plasticity changes in human brain samples [30] .
Because the AMY is a part of a set of defensive survival circuits and its activation contributes to feelings of fear [2] and the anterior hippocampus (aHIP) is mostly connected to the AMY and associated with emotional encoding [31] , we investigated whether the occurrence of IF was differentially associated with the levels of the GluA1 subunit and its phosphorylation at the Ser831 and Ser845 sites in the AMY and aHIP of MTLE-HS patients. For comparison, we analysed samples resected from the middle temporal neocortex (CX). We also investigated if the IF and the levels of the GluA1 subunit and its phosphorylation in the AMY and aHIP were independently associated with the psychiatric diagnosis and symptoms found in our patients.
Materials and methods

Patients
Thirty-one adult patients who were surgically treated between May 2009 and December 2012 at Centro de Epilepsia de Santa Catarina were prospectively included in this study, which was approved by the Ethics Committee for Human Research of Universidade Federal de Santa Catarina (365-FR304969). Written informed consent was obtained from all participants. They had seizures impairing awareness at least once a month despite adequate treatment with antiepileptic drugs (AEDs). The anamnesis, neurological examination, psychiatric and neuropsychological evaluation, surface video electroencephalography (VEEG) analysis and magnetic resonance imaging (MRI, 1.5 Tesla) were consistent with unilateral MTLE-HS [7-9, 32-37, 32] . The analysed variables were gender, race, marital status, current work activity, history of initial precipitating injury, laterality of HS, AEDs, psychiatric diagnosis, age, level of education, disease duration, monthly frequency of seizures and quality of life. Psychiatric diagnoses were determined by the Fourth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) [38] and the identification of psychiatric conditions frequently associated with epilepsy [33, 39, 40] . Quality of life was evaluated using the Quality of Life in Epilepsy Inventory-31 (QOLIE-31) [7, 8, 41] . Anxiety and depressive symptoms were assessed by the Hospital Anxiety and Depression Scale (HADS) [33, 36, 37, 42] in the last 26 patients who were included in the study.
Characterization of IF and other epileptic auras
Patients were evaluated by a board-certified clinical neurophysiologist with expertise in epilepsy surgery and who were well familiar with auras, including IF. In all patients, the seizure semiology was essentially the same for several years. The reported auras included epigastric, cephalic, fear, déjà vu, sternal, jamais-vu, dizziness, autonomic, olfactory, gustatory, sensations of ascending body chills or poorly defined symptoms. Patients described only one type of aura or a sequence of two or three different auras.
The analysis of objective electrocardiographic (ECG), electroencephalographic (EEG) and behaviour parameters associated with IF during the VEEG evaluation remains a challenge in the clinical scenario because: (1) there is a substantial delay between the EEG signal spread from deep limbic structures when the symptoms start until the scalp electrodes are reached; (2) the occurrence of movementrelated artefacts affecting the surface EEG and ECG signal; (3) variations in the patient position, room luminosity and even the presence of blankets covering the patient make it difficult to carry out a systematic behaviour analysis; and (4) usually, when the clinical testing starts during the seizure, there are variable levels of language dysfunction or awareness impairment.
Because of these limitations, a careful evaluation of the subjective component of the IF reported by the patient during the neurologic interview, avoiding suggestive questioning, remains the core stone for IF diagnosis. As previously described [14] , IF can be confirmed only if (1) the symptom onset is abrupt; (2) it was reported as being concomitant with an epileptic seizure; (3) it arose spontaneously out of context without any external or mental motivation; and (4) it could be clearly distinguished from fear of a seizure. Our interview included the following questions: (1) do you know or feel when your seizures start? If yes; (2) how do you know, what do you feel? (3) if the patients described perception using the words "fear", "fear sensation", "sensation of death", "thoughts of dread", "impending death" or "bad feeling of fear" we ask: is this "fear" because you realize that you will have a seizure and are afraid of that? To be considered ictal fear the patient need to clarify the "fear" is not because he or she realizes the seizure is starting; (4) you can identify some motivation for this "fear"? and the answer must be negative; (5) this feeling occurs slowly, during some time like minutes or hours or start abruptly? and the answer must be "start abruptly".
Patients who could not remember any type of aura were classified in the group without aura (see the supplementary table 1). A careful VEEG analysis showed that all patients with IF (n = 06) showed a horrified, tense or preoccupied facial expression during the seizure. Of the 25 patients who did not report IF, 2 showed facial behaviour that suggested fear during their seizures. However, because they did not report ictal fear, they were classified in the group without IF. No patient had hypermotor behaviour that suggested frontal lobe semiology.
Anaesthesia protocol
The anaesthetic protocol was the same for all patients [30] , starting between 7:30 and 8:30 a.m. with intravenous (i.v.) bolus of propofol (2 mg/kg), fentanyl (2 µg/kg) and rocuronium (0.9 mg/kg), followed by i.v. remiphentanil infusion (0.1-0.2 µg/kg/min) and isofluorane inhalation (0.5-0.6 minimum alveolar concentration). A dexamethasone bolus (10 mg i.v.) was infused immediately after intubation as an adjunctive anti-inflammatory in 20 patients. Hydration was done with isotonic saline (1.2 ml/ kg/h) plus the half volume of diuresis. Cephalotine (30 mg/ kg) was given 30 min before the anaesthesia. Oral AEDs were maintained until the day of surgery (6 a.m.). Patients received 20 mg/kg of phenytoin i.v. 12 h before the surgery and those under phenytoin at home only received their oral dose at the day of surgery. All patients received a phenytoin bolus (5 mg/kg i.v.) after the brain samples were collected.
Surgery, intraoperative variables and brain tissue sampling
The analysed samples from brain tissue were removed by a standard anterior and temporal lobectomy [7, 8, 9] without thermo-coagulation following the recommended prospective collection model [43] as previously described [30, 44] . A 1 cm 2 sample of middle temporal cortex (CX) localized 3 cm posterior to the temporal lobe pole was gently dissected from the white matter. After assessing the mesial temporal region, two-thirds of the AMY, including its basal and lateral nucleus, were resected. Finally, the HIP head and body were removed "en bloc", and the aHIP was quickly dissected on ice-refrigerated glass. Immediately after collection, the samples were transferred to an Eppendorf tube, frozen in liquid nitrogen and stored in a −80°C freezer for later analysis. The anaesthesia duration for collecting the brain samples was controlled. Arterial blood gases, electrolytes, haematocrit/haemoglobin, pH, mean arterial pressure, heart and respiratory rate during the AMY/ aHIP sampling were controlled. Haemodynamic and respiratory parameters remained stable during all procedures, and there were no surgical complications.
Biochemical analysis
All samples were homogenized by the same researcher on the same day and stored at −80 o C until the analysis. The phosphorylation levels and total amount of target proteins were determined in a blinded manner for all clinical data by western blot (WB) as previously described [30, [45] [46] [47] . Briefly, the brain samples were mechanically homogenized in buffer solution containing 50 mM Tris, pH 7.0, 1 mM EDTA, 100 mM NaF, 0.1 mM phenylmethylsulfonyl fluoride, 2 mM Na 3 VO 4 , 1% Triton X-100, 10% glycerol, protease inhibitor cocktail and centrifuged 10,000 × g at 4°C for 10 min. The supernatants were diluted in electrophoresis buffer. The protein content was estimated by the method described by Peterson [48] . The proteins (60 µg per track) were electrophoresed in 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Proteins were detected with selective antibodies (anti-phospho-GluA1-Ser831 (SigmaAldrich, A4352); anti-phospho-GluA1-Ser845 (SigmaAldrich, A4477); anti-total-GluA1 (Santa Cruz Biotechnology, sc-13152); anti-PP1 (Santa Cruz Biotechnology, sc-7482); anti-phospho-PKA substrates (Cell Signaling, #9624); anti-EAAT1 (Cell Signaling, #5684); anti-EAAT2 (Cell Signaling, #3838); anti-GFAP (Cell Signaling, #3670)) in a 1:1000 dilution. The blots were developed by chemiluminescent reaction. For load control all membranes were incubated with anti-β-actin antibody (Santa Cruz Biotechnology, sc-47778, 1:2000). The phosphorylation level was determined as a ratio of the optic density (OD) of the phosphorylated band relative to the OD of the total band. The protein immunocontent was determined as a ratio of the OD of the protein band to the OD of the β-actin band [30] . Due to the lack of brain tissue samples from healthy controls, an internal control sample was applied as a reference in all electrophoresis. The reference sample was obtained from three pooled HIP prepared as all other samples. The OD ratio (phosphorylated/total or total/ β-actin) for each target protein in the reference sample was considered 100% and the data were expressed as percentage variation from the reference sample [30] .
Statistical analysis
Continuous variables showed a normal distribution (Kolmogorov-Smirnov, p < 0.10) and differences between patients with and without IF were analysed with Student's ttest and the equality of variances assumption for neurochemical variables was verified (p > 0.15 by Levene's test). Categorical variables were analysed by Fisher's exact test. Pearson's coefficient was used for analysis of correlations. The pre-test power of analysis to find a 20% difference between the means of neurochemical marker levels of the two groups (with and without IF) with a SD of 15% of means was 80%. Because we had a predetermined hypothesis and to avoid a type II error, no corrections for multiple comparisons were applied, and p < 0.05 was considered statistically significant.
A univariate analysis was done to identify imbalances in the distribution of demographic, clinical, laboratorial and neurosurgical variables between patients with and without IF with a p < 0.20. These variables were included in a multiple binary regression analysis to determine the independent association between IF and the target variables.
Results
In all, 6 patients (19.4%) had no aura, 25 (80.6%) had at least one aura type and 6 (19.4 %) had IF alone or in combination with other auras (supplementary table 1). Table 1 shows that patients with IF had lower levels of GluA1 (−11%) in the AMY (p = 0.05) but not in the aHIP (p = 0.82) and CX (p = 0.38) compared to patients without IF. Patients reporting IF also had 21.5% lower levels of P-GluA1-Ser845 in the aHIP (p = 0.009) but not in the AMY (p = 0.28) and CX (p = 0.20). Patients with IF showed a non-significant trend (p = 0.14) for lower levels of P-GluA1-Ser831 in the aHIP, but not in the AMY and CX, compared to patients without IF. The results remained unchanged when the two patients without IF who exhibited facial expressions of fear were excluded from the analysis (p = 0.03 for the AMY levels of GluA1 subunit and p = 0.01 for the aHIP levels of P-GluA1-Ser845, data not shown). Because IF could be related to imbalances in tissue gliosis, we compared the levels of glial fibrillary acidic protein (GFAP) between patients reporting or not reporting IF (Table 1 ). There were no differences in the GFAP levels in the AMY (p = 0.75), aHIP (p = 0.52) and CX (p = 0.84) between patients with or without IF. There was also no correlation between the GluA1 subunit and the GFAP levels in the AMY (r = 0.03, p = 0.88, data not shown).
As a second marker of gliosis, and because glutamate transmission could be affected by changes in glutamate reuptake by astrocytes, the levels of excitatory amino acid transporter type 1 and 2 (EAAT1 and EAAT2) were determined in the same analysed samples (Table 1) . No significant association (p ≥ 0.64) was observed between the occurrence of IF and the levels of EAAT1 and EAT2 in all of the analysed structures.
Multiple linear regressions were performed to investigate the independent association between the levels of the GluA1 subunit in the AMY or P-GluA1-845 in the aHIP and the IF (see Suppl. Table 2 ). After controlling for the distribution of other frequent auras, only IF was independently associated with aHIP levels of P-GluA1-Ser45 (supplementary table 2, final model 1) or the AMY levels of the GluA1 subunit (supplementary Table 2 , final model 2).
The demographic and clinical variables are shown in Table 2 . The patients were mostly female (58.1%), had a mean age of 36.4 years, 6.6 years of education, 9 seizures impairing awareness per month and 24 years of disease duration. None of the investigated variables were significantly associated with the occurrence of IF. There was a non-significant trend (p = 0.17) for lower prevalence of IF in patients taking benzodiazepines. Supplementary Table 3 shows that surgical and laboratory variables, e.g., storage time of samples and time since the last seizure before surgery, were not associated with IF. There was a nonsignificant trend for higher levels of arterial PO 2 pressure during surgery (p = 0.13) and longer storage time (p = 0.15) for the samples from patients with IF (supplementary Table 3 ). Table 3 shows that after controlling for imbalances in the distribution of the arterial PO 2 , benzodiazepine use and time of sample storage with multiple binary regression, the presence of IF remains independently associated with aHIP levels of P-GluA1-Ser845 (adjusted odds ratio (OR) 0.92, confidence interval (CI) 95% 0.85-0.99, p = 0.04) and Considering the biological plausibility and the small sample size, we believe the observed trend (p = 0.09) was a false negative result and both biomarkers were maintained in the final binary regression model ( Table 3 ). The aHIP levels of P-GluA1-Ser845 alone had an overall accuracy of 92.1% (specificity 95.5% and sensitivity 33.3%) to predict the occurrence of IF. The AMY levels of the GluA1 subunit alone had an overall accuracy of 87.2% (specificity 100% and sensitivity 33.3%) to predict the occurrence of IF. Together, the AMY levels of GluA1 and the aHIP levels of P-GluA1-Ser845 showed an overall accuracy of 89.3% (specificity 95.5% and sensitivity 66.7%) to predict the IF occurrence.
Because protein kinase A (PKA) phosphorylates and the serine/threonine-protein phosphatase PP1-alpha catalytic subunit (PP1) dephosphorylates GluA1-Ser845, we investigated the correlation between the aHIP levels of P-GluA1-Ser845 and PKA activation or PP1. There was a significant positive correlation between PKA activation and P-GluA1-Ser845 levels (Fig. 1a) . The PP1 levels were not correlated with P-GluA1-Ser845 levels (Fig. 1b) . However, the multiple linear regression analysis revealed that only IF, but not the levels of PKA activation or PP1 levels, were independently associated with the aHIP levels of P-GluA1-Ser845 (Fig. 1) . The results indicate the association between IF and lower aHIP levels of P-GluA1-Ser845 was not related to changes in the levels of PKA activation or PP1.
Finally, IF was not associated with the psychiatric diagnosis (DSM criteria, p = 0.78) or with anxiety (p = 0.77) or depression (p = 0.53) symptoms (Table 2) . No significant correlations were observed between the AMY levels of the GluA1 subunit and HADS scores for anxiety (Fig. 2a , r = 0.27, p = 0.21) or depression (Fig. 2b , r = 0.18, p = 0.41). Finally, the aHIP levels of P-GluA1Ser-845 were also not associated with HADS scores for anxiety (Fig. 2c , r = 0.08, p = 0.71) or depression (Fig. 2d , r = 0.04, p = 0.85).
Representative WB results are shown in suppl. Figure 1 .
Discussion
Patients with unilateral drug-resistant MTLE-HS and IF had significantly lower levels of P-GluA1-Ser845 in the aHIP and GluA1 subunit in the AMY ipsilateral to the HS than patients without IF. The association between P-GluA1-Ser845 levels and IF was not related to changes in PKA activation or PP1 levels in the aHIP. The phosphorylation of GluA1-Ser845 also can be modulated by protein phosphatases 2A and 2B [27] as well as by protein kinase G [49] . Furthermore, GluA1-Ser-845 can also be modified by O-linked N-acetylglucosamine (O-GlcNAc) [50] , a post-translational modification regulated by O-GlcNAc transferase (OGT) and O-GlcNAcase, which are enzymes that were not analysed in this present study. It should be noted that this process could impair GluA1-Ser-845 phosphorylation and might be associated with hippocampal LTD [50] . Therefore, these mechanisms might affect GluA1-Ser845 phosphorylation and deserve further investigation. Using MRI, Cendes et al. [13] showed that MTLE-HS patients reporting IF had a significant reduction in their AMY volume (16%) compared to patients without IF, and their post-operative histopathology correlated well with AMY atrophy [13] . We believe the 11% reduction in the AMY levels of the GluA1 subunit observed in our patients with IF may reflect the neurochemical aspects of the MRI results reported by Cendes at al. [13] several years ago. In rodents, the HIP encodes contextual aspects of conditioned fear and has major projections to both the prefrontal cortex and the basolateral AMY [51] . Inhibitory avoidance learning promotes an increase in P-GluA1-Ser831 but not GluA1-Ser-845 in HIP synaptoneurosomes [23, 52] . The phosphorylation pattern of these two sites of the GluA1 subunit in relation to fear memory resembles what occurs in the LTP induced in posterior hippocampal area CA1 by high-frequency stimulation [23, 53] . In addition, phosphorylation of the GluA1 subunit at Ser845 by PKA has been implicated in the enhancement of AMPARmediated currents [54, 55] , insertion of AMPARs into the postsynaptic membrane [54, 56] and LTP induction after prior LTD [29] . During LTD, the P-GluA1-Ser845 levels may be decreased [56, 57] and associated with the removal of AMPARs from synapses, whereas LTP is associated with the delivery of AMPARs to synapses [25, 28, 29] . Our results may indicate an LTD-like neuroplasticity in the aHIP of patients showing IF compared to patients without IF. Moreover, in contextual fear conditioning, the increased HIP levels of P-GluA1-Ser831 seem to be specifically associated with learning rather than a non-specific effect of aversive stimuli (such as a foot shock or novel context exposure) [23, 52, 53, 58] . This outcome could mean that the slight, but not significant, decrease in Ser831 phosphorylation in the aHIP (p = 0.14) observed in this study is an indication that IF is distinct from fear conditioning.
The association between the lower aHIP levels of PGluA1-Ser-845 and IF may be related to previous findings collected with magnetic resonance spectroscopy that show a higher degree of neuronal dysfunction in the aHIP of MTLE-HS patients reporting IF [14] . Taken together, both results agree with the classical view of a functional role for aHIP within fear and anxiety-related behaviours and the endocrine stress response [31] . In physiological conditions, fear caused by exposure to threats results in stress responses [1, 59] . Increased levels of glucocorticoids released during chronic stress reduces dendritic branching and spine count in the rat hippocampus [60, 61] and has been associated with HIP atrophy [62] and psychiatric illness, including anxiety and mood disorders [3] . However, we did not find any association between the psychiatric diagnoses or symptoms of depression or anxiety and the presence of IF as well as the aHIP levels of P-GluA1-Ser-845 and the AMY levels of the GluA1 subunit.
The relationship between fear caused by exposure to real or imagined threats and the unmotivated aura of fear in temporal lobe epilepsy seizures is unknown. The differential diagnosis between panic attacks and IF can be challenging [15, 63] , and several findings suggest that both disorders can be part of a continuum of abnormal hyperexcitability or involvement of defensive survival circuits [63] [64] [65] . We speculate that our findings in patients with MTLE-HS may have some implications for the role of neuroplasticity in panic attacks. Testing this idea will require some ingenuity since the occurrence of spontaneous fear cannot be investigated under experimental conditions. Temporal lobe epilepsy surgery is the only opportunity to obtain samples from defensive survival circuit structures under adequate conditions to investigate biomarkers of synaptic plasticity. However, our study design does not allow us to make a definitive conclusion as to whether IF is a cause, consequence or an epiphenomenon of the lower levels of GluA1 in the AMY and P-GluA1-Ser-845 in the aHIP. Variations in gliosis in aHIP and the AMY of MTLE-HS [66, 67] patients could be a confounding bias in our study. Because histopathological analysis was not feasible in the samples used for WB analysis, determining the GFAP and astrocytic glutamate transporter levels were viable alternatives for controlling the gliosis distribution in our samples. The small sample size is a well-known limitation in WB studies, and false negative results are definitely possible. However, the significant associations that were found in a small sample strengthens the credibility of the results.
We would like to emphasize the positive aspects of our study: (1) the hypothesis was established prior to the analysis; (2) the prospective study design had a blinded analysis; (3) use of the HADS questionnaire avoided reliance on identifying aspects of the somatic symptoms of psychiatric illness; (4) the extensive control applied to clinical variables and collection of the brain samples; and (5) the multivariate analysis approach, which is rarely applied in studies using western blot results of protein phosphorylation under clinical scenarios. Therefore, we do believe that our results provide reliable information concerning neuroplasticity in fear-related brain structures. Taken together with previous findings in MTLE-HS patients with IF who were evaluated by stereotactic implanted depth electrodes [15] , we speculate our findings are consistent with the hypothesis that AMY is not a centre of fear but together with other subcortical and cortical structures integrates the defensive circuit that detect and respond to threats [2] .
In conclusion, recurrent IF is associated with lower levels of P-GluA1-Ser-845 in the aHIP and the GluA1 subunit in the ipsilateral AMY of patients with unilateral MTLE-HS. This is the first report to address neuroplasticity features in human limbic structures connected to the defensive circuit, which may have implications for understanding highly prevalent psychiatric disorders and symptoms. Fig. 1 Correlations between the variation in the level of PKA activation (a) and PP1 (b) in aHIP and the variation in the P-GluA1-Ser845 levels in the aHIP. Data are expressed as the level of the neurochemical parameter determined as percentage of the reference sample which was considered 100%. PKA activation was determined using an antibody against phospho-PKA substrates (indirect measure of PKA activation) which detects peptides and proteins containing a phosphoserine/threonine residue with arginine at the −3 and −2 positions, which is a consensus sequence that undergoes PKA-dependent phosphorylation. There was a significant positive correlation between the levels of PKA activation and the P-GluA1-Ser845 (r = 0.33, p = 0.04).
No association was observed between the P-GluA1-Ser845 and the PP1 levels (r = 0.10, p = 0.30). Statistical analysis done by Pearson's correlation (1-tailed). After the multiplelinear regression analysis (bottom of Fig. 1 ) only the presence of the IF, but not the levels of PKA activation and PP1, remain independently and negatively associated with the P-GluA1Ser845 variation in the aHIP. The validity of the model was confirmed by many aspects: there were no outliers, the data points were independent, the distribution of residuals satisfied the normality assumptions, the variance was constant and there was nomulticollinearity Fig. 2 Pearson's correlation between the neurochemical changes in AMY and aHIP and the psychiatric symptoms of MTLE-HS patients (n = 26). a AMY levels of GluA1 subunit and anxiety symptoms (HADS Anxiety); b AMY levels of GluA1 subunit and depression symptoms (HADS Depression); c aHIP levels of P-GluA1-Ser845 and anxiety symptoms (HADS Anxiety); d aHIP levels of P-GluA1-Ser845 and depressive symptoms (HADS Depression)
